logo
Share SHARE
FONT-SIZE Plus   Neg

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE: Quote), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Panera has banned more than 150 artificial ingredients from its food, and will remove all traces of the ingredients from its menu by 2016, the company confirmed Tuesday. Customers want a healthier menu, according to CEO Ron Shaich, who spoke with numerous media outlets about the changes. "We are... German department store operator Metro AG reported Tuesday a loss for the second quarter that widened from last year, despite sales growth, hurt by goodwill impairment at Real Germany. The company also confirmed its outlook for financial year 2014/15. Anadarko Petroleum Corp (APC) on Monday reported a wider-than-expected loss for the first quarter, crippled mostly by lower commodity prices.
comments powered by Disqus
RELATED NEWS
Trade GE now with 
Follow RTT